Julita Sadowski, MD
Family Medicine · Chicago, ILNPI 1508818659
Payments from drug & device makers
Across 138 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$643
- Johnson & Johnson$478
- AstraZeneca$369
- AbbVie$342
- GSK$249
- Novartis$185
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $643 |
| Johnson & Johnson | 9 | $478 |
| AstraZeneca | 21 | $369 |
| AbbVie(2 entities) | 18 | $342 |
| GSK | 12 | $249 |
| Novartis | 5 | $185 |
| Amarin Pharma, Inc. | 4 | $176 |
| Pfizer | 2 | $142 |
| Merck | 7 | $106 |
| Sumitomo Pharma America, Inc. | 6 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Sunovion Pharmaceuticals Inc. | 5 | $80 |
| Astellas Pharma US Inc | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $63 |
| Mylan Specialty L.p. | 3 | $54 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $37 |
| Boehringer Ingelheim | 1 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Exact Sciences | 1 | $26 |
| Eisai Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,341 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $73,276 |
| OzempicSemaglutide | 26 | $31,229 |
| JanuviaSitagliptin Phosphate | 13 | $21,051 |
| TradjentaLinagliptin | 17 | $20,195 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $16,187 |
| VascepaIcosapent Ethyl | 21 | $15,968 |
| LinzessLinaclotide | 20 | $11,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $9,662 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $6,095 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $4,973 |
| Metoprolol Succinate | 193 | $2,495 |
| Levothyroxine Sodium | 168 | $2,310 |
| Atorvastatin Calcium | 228 | $2,261 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 64 | $2,173 |
| Omega-3 Acid Ethyl Esters | 16 | $1,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $73,27680 claims |
| Novo NordiskOzempic | $643 | $31,22926 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $249 | $25,84942 claims |
| MerckJanuvia | $106 | $21,05113 claims |
| Boehringer IngelheimTradjenta | $31 | $20,19517 claims |
| AbbVieLinzess, Armour Thyroid | $342 | $12,38231 claims |
| AstraZenecaBreztri Aerosphere | $369 | $6,09512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.